TickerFacts.

Jyong Biotech Ltd. (MENS): Depreciation & Amortization

Annual figures by period end, from SEC filings.

$100.0K
Year ended 2025-12-31
$127.0K2023-12-31: $127.0K2024-12-31: $120.0K2025-12-31: $100.0K$100.0K
2023-12-31 Depreciation & Amortization (USD) 2025-12-31
Period endedDepreciation & AmortizationChange YoYSource filing
2025-12-31$100.0K-16.7%2026-05-15, From 2025-01-01
2024-12-31$120.0K-5.5%2026-05-15, From 2024-01-01
2023-12-31$127.0Kn/a2026-05-15, From 2023-01-01

Depreciation & Amortization at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedDepreciation & AmortizationChange YoY
Jyong Biotech Ltd. (MENS)2025-12-31$100.0K-16.7%
Incannex Healthcare Inc. (IXHL)2025-06-30$246.0K+138.8%
Nexentis Technologies Inc. (NXTS)2025-12-31$71.0K+294.4%
Emmaus Life Sciences, Inc. (EMMA)2025-12-31$39.0K+77.3%
Phio Pharmaceuticals Corp. (PHIO)2025-12-31$3.0K+50.0%
Galectin Therapeutics Inc (GALT)2024-12-31$0n/a
Moleculin Biotech, Inc. (MBRX)2025-12-31$90.0K-28.6%
Lftd Partners Inc. (LIFD)2025-12-31$552.9K+6.2%
Gain Therapeutics, Inc. (GANX)2025-12-31$94.0K+11.9%

Compare MENS, IXHL, NXTS, EMMA side by side · Screen every company in Pharmaceutical Preparations ↗